A new breakthrough in chromosome silencing offers a potential treatment pathway for trisomy 21

A recent study published in PNAS presents a breakthrough in Down syndrome research by optimizing a strategy to silence the extra chromosome 21 (primarily responsible for the disorder) through integration of the XIST (X-inactive specific transcript) gene using CRISPR-Cas9 technology. This approach, inspired by the natural mechanism of X-chromosome inactivation, markedly improves specificity and efficiency in in vitro studies, opening new avenues for therapy to correct the gene imbalance characteristic of trisomy 21. Alongside its potential, however, important scientific and bioethical questions arise—particularly regarding its possible application in human embryos and the risks associated with gene editing—inviting us to reflect on the limits and responsibilities of science.

Down Syndrome (DS), etiologically linked to the presence of a third copy of human chromosome 21 (HSA21), leads to an imbalance in gene dosage and dysregulation of the cell transcriptome.

A study recently published in the prestigious journal PNAS describes a new methodology that optimizes integration of the XIST gene as a molecular therapeutic strategy.^[1]

X Chromosome Silencing Mimicry

The approach is based on translation of the “lyonization” mechanism, whereby one of the two X chromosomes is naturally inactivated in the cells of early female mammalian embryos during the first embryonic cell divisions. Although this phenomenon occurs randomly through inactivation of either the paternal or maternal X chromosome in each cell, its ultimate physiological outcome is “gene dosage compensation in mammals”. In other words, after the embryonic stage, for the purposes of gene expression, only one of the X chromosomes remains active in both female and male mammals. The factor responsible for this inactivation is the XIST gene, which produces a long noncoding RNA XIST (lncRNA) that acts as the primary effector of X chromosome inactivation (XCI). Its function is to recruit chromatin-modifying complexes that induce epigenetic changes (such as DNA methylation and histone deacetylation), transforming euchromatin into transcriptionally inert facultative heterochromatin. This process is known as gene “silencing”, i.e., preventing specific genes from coding for certain proteins associated with the dysfunction targeted for correction.

Previous attempts have sought to use this mechanism to selectively silence one of the three copies of chromosome 21, leaving the other two active. Another challenge is that the chromosome chosen for silencing is the same in all cells of the organism on which it acts, whether embryo or adult. At present, the techniques required are being tested in in vitro cell systems.

Background

As we have comprehensively reported previously, other trials that have attempted to silence the extra chromosome in DS have succeeded in inserting the XIST gene into the Dyrk1a locus of chromosome 21 in induced pluripotent stem cells (iPSCs) derived from the fibroblasts of an individual with DS.

Earlier attempts using zinc finger nucleases (ZFNs) faced major hurdles, such as low transfection and integration efficiency due to the large size of the XIST gene sequence (~14 kb), which impeded its delivery and targeted insertion; lack of allelic specificity also made it difficult to direct integration exclusively to the extra copy without affecting the disomic copies, which are necessary.

Developments in ongoing research

The study published in PNAS presents an optimized protocol that increases the genomic integration efficiency to 20-40% of cells using four technical strategies related to the use of CRISPR-Cas9 genome editing technology.

1. Cas9-exonuclease (Cas9-exo) fusion.

To optimize the efficacy of CRISPR-Cas9, a fusion protein was designed combining Cas9 with a λ-phage exonuclease. This modification generates single-stranded overhangs at the target DNA and donor vector cleavage sites, favoring the targeted non-homologous end-joining (NHEJ) repair pathway or recombination mechanisms that enhance insertion efficiency. This facilitates more precise integration of the XIST gene.

2. Designing SNP-specific sgRNAs.

Single nucleotide polymorphisms (SNPs) were employed to selectively silence the extra chromosome targeted. Four single guide RNAs (sgRNAs) were designed by searching for unique SNPs distinct between the three copies of chromosome 21. This would ensure that the action of CRISPR/Cas9 would be consistently exerted on the same chromosome in different cells.

3. Tandem sgRNA assembly.

The use of plasmid PX459 to express multiple sgRNAs in tandem optimizes the Cas9-cutting efficiency. Two of the guides target the gene acceptor locus and the other two the donor plasmid, maximizing the release of the XIST sequence and its subsequent integration into the target site.

4. Modification of the donor vector and transcriptional control.

The donor plasmid—which is required for integration of the XIST sequence into the genome of the recipient cells—was engineered to disable its autonomous replication and allow for inducible expression. This provides temporal control over XIST activation, allowing scientists to examine the reversibility of cell phenotypes associated with trisomy.

All these modifications of the CRISPR method greatly improved the integration efficiency of the long XIST gene (14 kb) into a specific chromosome 21, which is very important in order to avoid off-target effects. Partial silencing of the selected chromosome 21 was confirmed using a number of other techniques:  PCR, cell cloning, immunostaining and FISH.

New perspectives and ethical issues

This breakthrough provides fresh insights into the treatment of aneuploidy. The ability to integrate large sequences with high allelic specificity reduces the risks of unwanted (off-target) side effects and lays the groundwork for future chromosomal therapy interventions in early developmental stages or in specific cell lines affected by gene dosage.

The ability to implement effective and selective silencing, precisely targeting the chromosomal regions intended for inactivation, brings the approach to DS closer to an effective treatment. This was the wish of Jérôme Lejeune, a prestigious geneticist who identified trisomy of chromosome 21 as the genetic cause of this syndrome.

However, we must not overlook the fact that current advances are restricted to interventions on cell populations derived from mouse embryo fibroblasts cultured in vitro. Now comes the hardest part: translating in vitro findings to in vivo models. This entails applying this gene editing—insertion of the XIST gene followed by silencing of the genes located on the extra chromosome in DS—to all the cells of the affected individual. Since this cannot be achieved in adults, it would require genetically modifying early embryos, such that all the cells in the resulting organism incorporate these modifications.

This approach is not feasible at present due to the immense risks involved in massive genetic modification of an embryo, the future consequences of which are unpredictable.

The possibility of causing unintended alterations in gene expression—considering the still poorly understood interconnection of the different sequences of an individual’s entire genome—constitutes a currently insurmountable barrier that limits the application of these experiments in human embryos. In fact, the moratorium adopted at several international scientific meetings on the use of CRISPR/Cas9 modification techniques in germline and human embryos remains in effect.^[2]

Finally, the applications of this new advance in gene insertion and silencing must be strictly regulated to prevent eugenic practices, which seek to obtain “designer” genomes in which certain traits are enhanced or new ones incorporated, as intended by transhumanist and post-humanist movements.

Nicolás Jouve

Professor Emeritus of Genetics at the University of Alcalá

Member of the Bioethics Observatory of the Catholic University of Valencia

Julio Tudela

Director of the Institute of Life Sciences

Catholic University of Valencia

References:

[1] Lian, G., Khabazeh, A., Sheen, V. A modified CRISPR/Cas9 approach in silencing the triplication in Down syndrome: A treatment path XISTs. PNAS.  123 (16) (2026) e2517953123. https://doi.org/10.1073/pnas.2517953123

[2] Baltimore, D., Berg, P., Botchan, M. et al. Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science. 348 (6230) (2015) 36–38.